Cover Image
Market Research Report

Immunofluorescence Assay Market by Product (Reagent, Primary & Secondary Antibody, Kit, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023

Published by MarketsandMarkets Product code 610197
Published Content info 194 Pages
Immediate Delivery Available
Price
Back to Top
Immunofluorescence Assay Market by Product (Reagent, Primary & Secondary Antibody, Kit, Imaging Equipment, Immunofluorescence Microscopy), Type (Direct, Indirect), Disease (Cancer, Cardiovascular, Infectious Disease) & End User - Global Forecast to 2023
Published: February 28, 2018 Content info: 194 Pages
Description

"The global immunofluorescence assay market projected to grow at a CAGR of 5.8%."

The immunofluorescence assay market is expected to reach USD 2.01 billion by 2023 from an estimated USD 1.51 billion in 2018, at a CAGR of 5.8%. The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare expenditure are the major factors driving the growth of the significant growth drivers of the immunofluorescence assay market. However, high cost of instruments and implementation of excise duty by the US government are expected to limit the growth of immunofluorescence assay market during the forecast period.

"The kits segment is expected to register the highest CAGR during the forecast period."

On the basis of product, the immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables & accessories. The kits segment is expected to register the highest CAGR during the forecast period. The growth of this segment is primarily attributed to the increasing demand for complete solutions from a single-provider, the rising prevalence of a number of diseases, increasing R&D spending, and increased government funding for life science research.

"Indirect immunofluorescence segment dominated the market in 2017"

On the basis of type, the immunofluorescence assay market is segmented into indirect and direct immunofluorescence. The indirect immunofluorescence segment accounted for the largest share and it is also expected to register the highest CAGR during the forecast period. Factors contributing for its high growth include its advantages over direct immunofluorescence, such as sensitivity, flexibility, and lower cost.

"Cancer segment dominated the market in 2017"

Based on disease, the immunofluorescence assay market is segmented into cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, and other diseases (kidney diseases, neurological diseases, skin diseases, gastrointestinal diseases, and oral diseases). In 2017, the cancer segment accounted for the largest share in the global immunofluorescence assay market owing to the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.

"Hospitals and Diagnostics is expected to grow at the fastest rate during the forecast period"

On the basis of end user, the immunofluorescence assay market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, hospitals and diagnostics centers, and contract research organizations (CROs). The hospitals and diagnostic centers segment is expected to register the highest CAGR during the forecast period owing to the increasing use of immunofluorescence assay in the diagnose or identify of various diseases.

"APAC is projected to witness the highest growth during the forecast period"

North America held the largest share of the global immunofluorescence assay market in 2017. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing R&D spending, rising prevalence of diseases, large population in countries such as China and India, improving healthcare infrastructure, increasing healthcare spending, and government initiatives in this region.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-35%, Tier 2-40% and Tier 3-25%
  • By Designation - C-level-33%, Director Level-41%, Others-26%
  • By Region - North America-35%, Europe-30%, Asia Pacific-21%, Rest of World-14%

The prominent players in the global immunofluorescence assay market are: Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).

Research Coverage:

The report analyzes the various immunofluorescence assay products and their adoption pattern. It aims at estimating the market size and future growth potential of the global immunofluorescence assay market for different segments such as product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on product portfolios offered by the top players in the global immunofluorescence assay market
  • Product Development/Innovation: Detailed insights on upcoming trends, research and development activities and product launches in the global immunofluorescence assay market
  • Market Development: Comprehensive information on the lucrative emerging regions by product, type, disease, end user, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global immunofluorescence assay market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global immunofluorescence assay market
Table of Contents
Product Code: BT 6044

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
    • 1.3.3. CURRENCY
  • 1.4. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY SOURCES
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY SOURCES
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. IMMUNOFLUORESCENCE ASSAY: MARKET OVERVIEW
  • 4.2. IMMUNOFLUORESCENCE ASSAY MARKET: DEVELOPED VS. DEVELOPING COUNTRIES
  • 4.3. GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAY MARKET (2017)
  • 4.4. GEOGRAPHIC MIX: IMMUNOFLUORESCENCE ASSAY MARKET
  • 4.5. IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. KEY MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Increasing prevalence of chronic diseases
      • 5.2.1.2. Increasing R&D spending
      • 5.2.1.3. Increasing healthcare spending
    • 5.2.2. MARKET RESTRAINTS
      • 5.2.2.1. High cost of instruments
      • 5.2.2.2. Implementation of excise duty by the US government
    • 5.2.3. MARKET OPPORTUNITIES
      • 5.2.3.1. High growth opportunities in emerging markets
    • 5.2.4. MARKET CHALLENGES
      • 5.2.4.1. Quality concerns over research antibodies

6. IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT

  • 6.1. INTRODUCTION
  • 6.2. REAGENTS
    • 6.2.1. STAINS & DYES
    • 6.2.2. MEDIA & SERA
    • 6.2.3. FIXATIVES
    • 6.2.4. BUFFERS
    • 6.2.5. PROBES
    • 6.2.6. SOLVENTS
    • 6.2.7. OTHER REAGENTS
  • 6.3. INSTRUMENTS
    • 6.3.1. MICROSCOPES
    • 6.3.2. IMAGING ANALYSIS SYSTEMS
  • 6.4. ANTIBODIES
    • 6.4.1. PRIMARY ANTIBODIES
    • 6.4.2. SECONDARY ANTIBODIES
  • 6.5. KITS
  • 6.6. CONSUMABLES & ACCESSORIES

7. IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. INDIRECT IMMUNOFLUORESCENCE
  • 7.3. DIRECT IMMUNOFLUORESCENCE

8. IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE

  • 8.1. INTRODUCTION
  • 8.2. CANCER
  • 8.3. INFECTIOUS DISEASES
  • 8.4. CARDIOVASCULAR DISEASES
  • 8.5. AUTOIMMUNE DISEASES
  • 8.6. OTHER DISEASES

9. IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER

  • 9.1. INTRODUCTION
  • 9.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3. ACADEMIC & RESEARCH INSTITUTES
  • 9.4. HOSPITALS & DIAGNOSTIC CENTERS
  • 9.5. CONTRACT RESEARCH ORGANIZATIONS

10. IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. UK
    • 10.3.3. FRANCE
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE
  • 10.4. ASIA PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA PACIFIC
  • 10.5. LATIN AMERICA
  • 10.6. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET LEADERSHIP ANALYSIS
  • 11.3. GEOGRAPHIC REVENUE MIX OF THE MAJOR PLAYERS
  • 11.4. COMPETITIVE SCENARIO
    • 11.4.1. PRODUCT LAUNCHES
    • 11.4.2. EXPANSIONS
    • 11.4.3. ACQUISITIONS
    • 11.4.4. AGREEMENTS AND PARTNERSHIPS
    • 11.4.5. ANNOUNCEMENTS

12. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 12.1. THERMO FISHER SCIENTIFIC INC.
  • 12.2. ABCAM PLC
  • 12.3. BIO-RAD LABORATORIES, INC.
  • 12.4. PERKINELMER INC.
  • 12.5. MERCK MILLIPORE
  • 12.6. INOVA DIAGNOSTICS (A PART OF WERFERN COMPANY)
  • 12.7. CELL SIGNALING TECHNOLOGY, INC.
  • 12.8. MEDIPAN GMBH
  • 12.9. SINO BIOLOGICAL INC.
  • 12.10. DANAHER CORPORATION
  • 12.11. VECTOR LABORATORIES (A PART OF MARAVAI LIFESCIENCES)

*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. DISCUSSION GUIDE
  • 13.2. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.4. AVAILABLE CUSTOMIZATIONS
  • 13.5. RELATED REPORTS
  • 13.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 2: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 3: IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 4: IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 5: IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 11: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 12: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 15: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 16: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 18: SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 21: GLOBAL IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 22: COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES
  • TABLE 23: GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION/COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 24: GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAY MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 26: IMMUNOFLUORESCENCE ASSAY MARKET FOR CANCER, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 27: IMMUNOFLUORESCENCE ASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 28: IMMUNOFLUORESCENCE ASSAY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 29: IMMUNOFLUORESCENCE ASSAY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 30: IMMUNOFLUORESCENCE ASSAY MARKET FOR OTHER DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 32: IMMUNOFLUORESCENCE ASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 33: IMMUNOFLUORESCENCE ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 34: IMMUNOFLUORESCENCE ASSAY MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 35: IMMUNOFLUORESCENCE ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2016-2023 (USD MILLION)
  • TABLE 36: IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 39: NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 40: NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 41: NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 42: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 43: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 44: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 45: US: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 46: US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 47: US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 48: US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 49: US: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 50: US: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 51: US: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 52: CANADA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 53: CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 54: CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 55: CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 56: CANADA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 57: CANADA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 58: CANADA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 59: EUROPE: IMMUNOFLUORESCENCE ASSAY MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 60: EUROPE: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 61: EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 63: EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 64: EUROPE: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 65: EUROPE: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 66: EUROPE: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 67: GERMANY: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 68: GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 70: GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 71: GERMANY: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 72: GERMANY: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 73: GERMANY: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 74: UK: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 75: UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 76: UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 77: UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 78: UK: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 79: UK: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 80: UK: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 81: FRANCE: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 82: FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 83: FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 84: FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 85: FRANCE: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 86: FRANCE: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 87: FRANCE: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 88: ITALY: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 89: ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 90: ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 91: ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 92: ITALY: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: ITALY: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 94: ITALY: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 95: SPAIN: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 96: SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 97: SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 98: SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: SPAIN: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 100: SPAIN: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 101: SPAIN: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 102: ROE: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 103: ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 105: ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 106: ROE: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 107: ROE: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 108: ROE: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 109: APAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 110: APAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 111: APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 112: APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 113: APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 114: APAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 115: APAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 116: APAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 117: JAPAN: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 118: JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 119: JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 120: JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 121: JAPAN: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 122: JAPAN: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 123: JAPAN: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 124: CHINA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 125: CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 126: CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 128: CHINA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: CHINA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 130: CHINA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 131: INDIA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 132: INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 133: INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 134: INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: INDIA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: INDIA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 137: INDIA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 138: ROAPAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 139: ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 140: ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 141: ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: ROAPAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 143: ROAPAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 144: ROAPAC: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 145: LATIN AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 146: LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 147: LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 148: LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: LATIN AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 150: LATIN AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 151: LATIN AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 152: MEA: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 153: MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 155: MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 156: MEA: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 157: MEA: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 158: MEA: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 159: IMMUNOFLUORESCENCE REAGENTS, ANTIBODIES, AND KITS MARKET: COMPANY RANKING (2017)
  • TABLE 160: GROWTH STRATEGY MATRIX (2013-2017)
  • TABLE 161: PRODUCT LAUNCHES, 2013-2017
  • TABLE 162: EXPANSIONS, 2013-2017
  • TABLE 163: ACQUISITIONS, 2013-2017
  • TABLE 164: AGREEMENTS AND PARTNERSHIPS, 2013-2017
  • TABLE 165: ANNOUNCEMENTS, 2013-2017

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT, 2018 VS. 2023 (USD BILLION)
  • FIGURE 7: IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 8: IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE, 2018 VS. 2023 (USD BILLION)
  • FIGURE 9: IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER, 2018 VS. 2023 (USD BILLION)
  • FIGURE 10: GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAY MARKET
  • FIGURE 11: GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE IMMUNOFLUORESCENCE ASSAY MARKET DURING THE FORECAST PERIOD
  • FIGURE 12: DEVELOPING MARKETS TO REGISTER HIGHER GROWTH IN THE FORECAST PERIOD (2018-2023)
  • FIGURE 13: THE US ACCOUNTED FOR THE LARGEST SHARE OF THE IMMUNOFLUORESCENCE ASSAY MARKET IN 2017
  • FIGURE 14: NORTH AMERICA TO DOMINATE THE IMMUNOFLUORESCENCE ASSAY MARKET DURING THE FORECAST PERIOD
  • FIGURE 15: THE REAGENTS SEGMENT WILL CONTINUE TO DOMINATE THE IMMUNOFLUORESCENCE ASSAY MARKET IN 2023
  • FIGURE 16: IMMUNOFLUORESCENCE ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 17: CANCER PREVALENCE AND MORTALITY RATE, BY COUNTRY, 2012
  • FIGURE 18: PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2000 VS. 2010 VS. 2015
  • FIGURE 19: GLOBAL HEALTHCARE EXPENDITURE PER CAPITA, 2000 VS. 2010 VS. 2014
  • FIGURE 20: REAGENTS TO DOMINATE THE IMMUNOFLUORESCENCE ASSAY MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: INDIRECT IMMUNOFLUORESCENCE SEGMENT TO CONTINUE TO DOMINATE THE IMMUNOFLUORESCENCE ASSAY MARKET TILL 2023
  • FIGURE 22: CANCER SEGMENT DOMINATED THE IMMUNOFLUORESCENCE ASSAY MARKET IN 2017
  • FIGURE 23: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE IMMUNOFLUORESCENCE ASSAY MARKET IN 2023
  • FIGURE 24: IMMUNOFLUORESCENCE ASSAY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 25: NORTH AMERICA: IMMUNOFLUORESCENCE ASSAY MARKET SNAPSHOT
  • FIGURE 26: ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAY MARKET SNAPSHOT
  • FIGURE 27: KEY DEVELOPMENTS, 2013-2017
  • FIGURE 28: THERMO FISHER: COMPANY SNAPSHOT (2016)
  • FIGURE 29: ABCAM: COMPANY SNAPSHOT (2017)
  • FIGURE 30: BIO-RAD: COMPANY SNAPSHOT (2016)
  • FIGURE 31: PERKINELMER: COMPANY SNAPSHOT (2016)
  • FIGURE 32: MERCK MILLIPORE: COMPANY SNAPSHOT (2016)
  • FIGURE 33: WERFEN COMPANY: COMPANY SNAPSHOT (2016)
  • FIGURE 34: DANAHER CORPORATION: COMPANY SNAPSHOT (2016)
Back to Top